Showing 4,581 - 4,600 results of 7,608 for search '"oncology"', query time: 0.08s Refine Results
  1. 4581
  2. 4582
  3. 4583
  4. 4584

    Magnifying Endoscopy with Narrow Band Imaging to Determine the Extent of Resection in Transoral Robotic Surgery of Oropharyngeal Cancer by Ichiro Tateya, Seiji Ishikawa, Shuko Morita, Hiroyuki Ito, Tatsunori Sakamoto, Toshinori Murayama, Yo Kishimoto, Tomomasa Hayashi, Makiko Funakoshi, Shigeru Hirano, Morimasa Kitamura, Mami Morita, Manabu Muto, Juichi Ito

    Published 2014-01-01
    “…One of the most important factors for achieving success in TORS is the ability to determine the extent of resection during the procedure as the extent of resection in the laryngopharynx not only affects oncological outcomes but also directly affects swallowing and voice functions. …”
    Get full text
    Article
  5. 4585
  6. 4586
  7. 4587
  8. 4588
  9. 4589

    Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China by WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong

    Published 2024-11-01
    “…HER2 expression was significantly associated with various clinical and pathological characteristics such as Eastern Cooperative Oncology Group (ECOG) performance status, history of cardiovascular disease, history of metabolic disorders, smoking, UC disease location, differentiation grade, pathological type, and tumor stage. …”
    Get full text
    Article
  10. 4590
  11. 4591
  12. 4592
  13. 4593

    Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

    Published 2025-03-01
    “…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received pemetrexed (500 mg/m2) and pembrolizumab (200 mg) on day 1 of each 21-day cycle. …”
    Get full text
    Article
  14. 4594
  15. 4595
  16. 4596
  17. 4597
  18. 4598

    Clinical characteristics and outcomes of patients with chondroblastoma undergoing surgery with various adjuvant procedures: a retrospective study of 59 cases by Toru Hirozane, Tetsuya Sekita, Eisuke Kobayashi, Tomoaki Mori, Naofumi Asano, Toru Udaka, Takashi Tajima, Rumi Nakagawa, Kazutaka Kikuta, Akira Yoshiyama, Hideo Morioka, Itsuo Watanabe, Ukei Anazawa, Michiro Susa, Keisuke Horiuchi, Yoshihisa Suzuki, Takeshi Morii, Robert Nakayama

    Published 2025-01-01
    “…Two patients received preoperative denosumab and neither experienced local recurrence nor functional impairments. Conclusions Good oncological and functional outcomes were achieved. Age < 17 years was associated with a high risk of local recurrence after curettage (P = 0.0198). …”
    Get full text
    Article
  19. 4599
  20. 4600